T
TRiCares
Device designed for minimally invasive treatment of tricuspid regurgitation
About TRiCares
TRiCares is a medical device startup, founded in 2013, that operates in the rapidly growing transcatheter heart valve replacement market. The company's primary focus is on the development of a catheter-based tricuspid valve replacement system. This system is designed to help patients suffering from Tricuspid Regurgitation (TR), a serious heart complication where the tricuspid valve does not close properly, causing blood to flow back into the right atrium. This condition affects over 12.7 million patients in Europe alone.
TRiCares' innovative solution aims to treat TR without the need for open-heart surgery, offering a less invasive alternative to traditional surgical methods. This is particularly significant given the high-risk nature of open-heart surgeries and the potential for a faster recovery time with minimally invasive procedures.
The company's business model revolves around the development, production, and sale of these catheter-based systems to healthcare providers. By offering a unique and effective solution to a widespread health issue, TRiCares is well-positioned to capture a significant share of the heart valve replacement market.
The company is headquartered in Paris, France, with an additional office in Munich, Germany, serving a broad European market. TRiCares' potential for growth is substantial, given the high prevalence of heart valve disease and the increasing demand for minimally invasive treatment options.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Aschheim, Germany
- Employees
- 40
- Open positions
- None listed
- Dealroom signal
- 96.0/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Non-Invasive medical devices and treatments, biotech medtech and e-health, Observatoire Deeptech, Hard Tech, Horizon Europe, Digital Care, radar de l'innovation
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| DEBTDebt | Jan 2026 | $0 | — | European Investment Bank | ↗ |
| SERIES DOther financing | Jul 2024 | $50M | $200M | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for TRiCares is 400 monthly website visits, down 87.1% over the last three months. TRiCares's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Karista
European Innovation Council
Series A5 investors entered at this stage
Wellington Partners
BioMedVC
GO Capital
Andera Partners
Crédit Mutuel Equity
Series B and later2 investors entered at this stage
415 Capital
European Investment Bank
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about TRiCares on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TRiCares’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.